Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.
(2013) In Scientific Reports 3.- Abstract
- We used a single adeno-associated viral (AAV) vector co-expressing tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1) to investigate the relationship between vector dose, and the magnitude and rate of recovery in hemi-parkinsonian rats. Intrastriatal injections of >1E10 genomic copies (gc) of TH-GCH1 vector resulted in complete recovery in drug-naïve behavior tests. Lower vector dose gave partial to no functional improvement. Stereological quantification revealed no striatal NeuN+ cell loss in any of the groups, whereas a TH-GCH1 dose of >1E11 gc resulted in cell loss in globus pallidus. Thus, a TH-GCH1 dose of 1E10 gc gave complete recovery without causing neuronal loss. Safety and efficacy was also studied in non-human... (More)
- We used a single adeno-associated viral (AAV) vector co-expressing tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1) to investigate the relationship between vector dose, and the magnitude and rate of recovery in hemi-parkinsonian rats. Intrastriatal injections of >1E10 genomic copies (gc) of TH-GCH1 vector resulted in complete recovery in drug-naïve behavior tests. Lower vector dose gave partial to no functional improvement. Stereological quantification revealed no striatal NeuN+ cell loss in any of the groups, whereas a TH-GCH1 dose of >1E11 gc resulted in cell loss in globus pallidus. Thus, a TH-GCH1 dose of 1E10 gc gave complete recovery without causing neuronal loss. Safety and efficacy was also studied in non-human primates where the control vector resulted in co-expression of the transgenes in caudate-putamen. In the TH-GCH1 group, GCH1 expression was robust but TH was not detectable. Moreover, TH-GCH1 treatment did not result in functional improvement in non-human primates. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3956118
- author
- Cederfjäll, Erik
LU
; Nilsson, Nathalie
LU
; Sahin, Gurdal
LU
; Chu, Yaping ; Nikitidou, Elisabeth LU ; Björklund, Tomas LU ; Kordower, Jeffrey H and Kirik, Deniz LU
- organization
-
- Brain Repair and Imaging in Neural Systems (BRAINS) (research group)
- Translational Neuroendocrinology (research group)
- Associative Learning (research group)
- Neural Plasticity and Repair (research group)
- Molecular Neuromodulation (research group)
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scientific Reports
- volume
- 3
- article number
- 2157
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000321425700005
- pmid:23831692
- scopus:84880302312
- ISSN
- 2045-2322
- DOI
- 10.1038/srep02157
- language
- English
- LU publication?
- yes
- id
- a6107052-8c2f-4120-8f89-5c0e9e93870f (old id 3956118)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23831692?dopt=Abstract
- date added to LUP
- 2016-04-01 14:42:12
- date last changed
- 2022-01-28 02:03:42
@article{a6107052-8c2f-4120-8f89-5c0e9e93870f, abstract = {{We used a single adeno-associated viral (AAV) vector co-expressing tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1) to investigate the relationship between vector dose, and the magnitude and rate of recovery in hemi-parkinsonian rats. Intrastriatal injections of >1E10 genomic copies (gc) of TH-GCH1 vector resulted in complete recovery in drug-naïve behavior tests. Lower vector dose gave partial to no functional improvement. Stereological quantification revealed no striatal NeuN+ cell loss in any of the groups, whereas a TH-GCH1 dose of >1E11 gc resulted in cell loss in globus pallidus. Thus, a TH-GCH1 dose of 1E10 gc gave complete recovery without causing neuronal loss. Safety and efficacy was also studied in non-human primates where the control vector resulted in co-expression of the transgenes in caudate-putamen. In the TH-GCH1 group, GCH1 expression was robust but TH was not detectable. Moreover, TH-GCH1 treatment did not result in functional improvement in non-human primates.}}, author = {{Cederfjäll, Erik and Nilsson, Nathalie and Sahin, Gurdal and Chu, Yaping and Nikitidou, Elisabeth and Björklund, Tomas and Kordower, Jeffrey H and Kirik, Deniz}}, issn = {{2045-2322}}, language = {{eng}}, publisher = {{Nature Publishing Group}}, series = {{Scientific Reports}}, title = {{Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.}}, url = {{https://lup.lub.lu.se/search/files/4119557/4146446}}, doi = {{10.1038/srep02157}}, volume = {{3}}, year = {{2013}}, }